Peptides before shoulder replacement

A shoulder replacement recovery stack that combines TB-500, BPC-157, growth hormone, retatrutide, testosterone, an anabolic steroid, or other unapproved peptides is not something a forum can make safe. The useful next step before surgery is to give the orthopaedic and anaesthesia teams a complete list of medicines and products under consideration. Include peptide products and supplements. Include non-prescription items as well. The American College of Surgeons advises patients to bring a list of prescribed medicines and over-the-counter products. Vitamins or herbs belong on that list because medication plans may need adjustment before an operation.^[1]

Why a shoulder replacement recovery stack needs a clinical review

A shoulder replacement is a planned operation with an anaesthetic plan and a postoperative rehabilitation plan. A clinician who knows the surgical details can decide what information affects that plan. An online list of products cannot account for medical history or current medicines. It cannot replace instructions from the surgical team. Several compounds also make it harder to assess a new symptom after surgery.

A product's connection to repair does not establish human evidence for its use. Evidence would need to address the exact compound, formulation, and route. It would also need to address the surgical setting. A 2026 review for orthopaedic and sports medicine physicians examined injectable peptide approaches including TB-500, tesamorelin, and other compounds. It concluded that information on dosing and frequency remains unknown, as does treatment duration. More safety and efficacy research is needed before definitive patient recommendations can be made.^[2]

TB-500 does not have human orthopaedic evidence

TB-500 is often used as a label for a thymosin beta-4 fragment. The relevant preclinical work discusses tissue repair and angiogenesis, which means new blood-vessel formation. That mechanism is not the same as proof that a product improves recovery after shoulder arthroplasty, the operation commonly called shoulder replacement. The orthopaedic review found that TB-4 and its derivative TB-500 promoted angiogenesis and tissue repair in preclinical models, while human orthopaedic data were lacking.^[2] The TB-500 evidence page separates the research on full-length thymosin beta-4 from claims made for products sold as TB-500.

The FDA's compounding-safety page addresses the fragment LKKTETQ, also known as TB-500. The agency says compounded products containing it may pose immunogenicity risks for some routes because of possible aggregation and peptide-related impurities. Immunogenicity means the potential to trigger an immune response. The FDA also says it has not identified human exposure data for drug products containing that fragment and lacks important information about whether it could cause harm in people.^[3] This is not a prediction about one person's surgical outcome. It is a reason to avoid treating a vial label as a settled safety record.

Adding more compounds does not fill the evidence gap

The community question included more than one injury-recovery peptide plus hormones and metabolic drugs. Those products have different proposed uses and separate evidence files. A recent Sports Medicine review lists BPC-157 and TB-500 among unapproved peptides marketed directly to patients. It reports favorable findings in animal models for many compounds, but rigorous human safety data are scarce and potential for serious harm remains.^[4]

BPC-157 deserves its own assessment rather than being folded into TB-500 marketing. The orthopaedic review describes potential tendon and muscle-repair findings for BPC-157 as largely unvalidated in human trials. It notes a single human knee-injection case series with methodological flaws and no controls.^[2] Readers looking at that compound can start with the BPC-157 evidence page. Evidence about one experimental product does not establish safety for a combination, and evidence outside the shoulder-replacement setting does not establish a benefit within it.

What to tell the surgical team

Bring the actual names on the labels and the dates of recent use to the preoperative team. Include a full list of prescribed and non-prescription products. The American College of Surgeons specifically asks patients to bring a list of prescribed and over-the-counter medications, vitamins, and herbs, and says medication may need adjustment before an operation.^[1] If a product is a research chemical, a compounded preparation, or an online purchase, say that plainly. That gives the team the information needed to decide what matters for the procedure and recovery plan.

Do not use a forum thread to decide how to change substance use before an operation. We cannot give a dosing schedule or a product-specific perioperative plan. The surgical team and prescribing clinician are the appropriate people to reconcile medicines and explain their instructions. A disagreement between clinicians should be resolved by those clinicians, not by adding another product to the list.

What we do not yet know

There are no cited human trials here showing that TB-500 or BPC-157 improves shoulder-replacement recovery. The cited sources do not establish a benefit for the proposed combination either. We also do not have a reliable human safety record for TB-500 in this orthopaedic use. The existing literature does not establish an evidence-based dose or duration. It also does not establish a combination plan for this setting.^[2] The FDA's statement on the TB-500 fragment adds a separate uncertainty about human exposure and potential harm from compounded products.^[3]

The community post that prompted this article is a reader question, not clinical evidence. It cannot establish that any listed product helps. It also cannot establish that a product changes the course of one person's operation. A safe recovery discussion starts with the surgical team and the established postoperative plan, then stays honest about what unapproved products have not been shown to do.

Medical disclaimer: This article is for educational and journalistic purposes only and does not constitute medical advice. Peptides discussed may be classified as prescription medicines or research chemicals depending on your jurisdiction. Always consult a qualified healthcare professional before using any peptide product. PeptideMethods.com does not sell, distribute, or facilitate the sale of any peptide product.